HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results from a phase I ...
Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
MADISON, Wis.--(BUSINESS WIRE)--Invenra, a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data ...
While presenting this year’s Nobel Prize in Physiology or Medicine to three immunologists who discovered and characterized regulatory T cells, committee chair Olle Kämpe, M.D., Ph.D., told the ...
The EasySep™ Release Mouse CD4+ CD304+ Regulatory T-Cell Isolation Kit from STEMCELL Technologies is a mouse Treg isolation kit that targets the CD304 surface marker, which, unlike the CD25 Treg ...
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the ...
This article explores how the role of regulatory T cells in immunological self-tolerance evolved from skepticism to Nobel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results